FDA cited Yangzhou Yulou Paper Products for manufacturing violations after records showed its OTC sterile drugs lacked sterility assurance and testing.
What happened
FDA reviewed records the company submitted after a Feb. 10, 2025, records request; there was no inspection. The records did not show that OTC products labeled sterile were rendered sterile, and they did not show identity testing of components, stability data, process validation, or adequate quality-unit procedures. FDA also said the firm agreed to recall all sterile products from the U.S. market that were within expiry.
What FDA found
The firm did not show that its drug products labeled sterile were actually made sterile, and it lacked validated sterility testing and laboratory specifications.
21 CFR 211.113(b); 21 CFR 211.160(b)The firm did not test each incoming component to confirm its identity before use in manufacturing.
21 CFR 211.84(d)(1)The firm lacked stability studies to show its drug products remain acceptable through their labeled expiry date.
21 CFR 211.166(a)The firm had not validated its manufacturing processes and did not show routine testing or monitoring of a key ingredient/system that was redacted in the letter.
21 CFR 211.100(a)The firm's quality unit lacked written procedures for complaints, batch release, deviations, corrective actions, and other quality duties.
21 CFR 211.22(d)
What FDA wants
FDA asks the firm to respond in writing within 15 working days with corrective actions and plans addressing sterility assurance, component identity testing, stability, process validation, and quality-unit oversight. FDA also strongly recommends a qualified consultant to help with manufacturing-quality compliance.
Who should pay attention
- U.S. distributors and retailers of imported OTC drugs
- brands using Chinese contract manufacturers for OTC drug products
- supplier quality teams responsible for sterility assurance and component testing
This is a summary. Read the original letter on fda.gov.